Nextbio Capital Management

According to its website, the firm invests in breakthrough medicine through the application of next-generation technologies. This implies a focus on biotechnology companies leveraging advances in areas like artificial intelligence, machine learning, and digital health to improve drug discovery and development. Specific investment stages and financial instruments are not publicly detailed.

The firm lists offices in fourteen cities: Bentonville, Boston, New York, Greenwich, Austin, San Francisco, London, Montreal, Hamburg, Stamford, Paris, Amsterdam, Manhattan Beach, and Menlo Park. This extensive geographic footprint spans major life sciences and technology hubs in both North America and Europe, suggesting a distributed team or investment presence without a single dominant headquarters.

The firm has not publicly named its founders, managing partners, or investment committee members on its primary website as of the latest review. The absence of disclosed leadership is a significant information gap for due diligence and represents an opaque governance structure relative to most institutional-grade life sciences investors.

Nextbio Capital Management does not publicly disclose its assets under management or total capital deployed. Without disclosed fund sizes, regulatory filings, or named investment leads, the firm's financial scale cannot be independently verified. The AUM remains undisclosed.

The firm's legal and operational structure is not publicly defined. Its wide office network, lack of named partners, and straightforward strategy statement do not clearly map to either a traditional venture capital firm or a single-family office. The structural ambiguity makes it difficult to classify the firm or understand its capital sources and governance.